1. Home
  2. HTD vs TBPH Comparison

HTD vs TBPH Comparison

Compare HTD & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTD
  • TBPH
  • Stock Information
  • Founded
  • HTD 2004
  • TBPH 2013
  • Country
  • HTD United States
  • TBPH United States
  • Employees
  • HTD N/A
  • TBPH N/A
  • Industry
  • HTD Finance Companies
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTD Finance
  • TBPH Health Care
  • Exchange
  • HTD Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • HTD 863.8M
  • TBPH 699.0M
  • IPO Year
  • HTD N/A
  • TBPH N/A
  • Fundamental
  • Price
  • HTD $24.77
  • TBPH $17.89
  • Analyst Decision
  • HTD
  • TBPH Strong Buy
  • Analyst Count
  • HTD 0
  • TBPH 4
  • Target Price
  • HTD N/A
  • TBPH $24.25
  • AVG Volume (30 Days)
  • HTD 92.3K
  • TBPH 395.4K
  • Earning Date
  • HTD 01-01-0001
  • TBPH 11-10-2025
  • Dividend Yield
  • HTD 8.59%
  • TBPH N/A
  • EPS Growth
  • HTD N/A
  • TBPH N/A
  • EPS
  • HTD N/A
  • TBPH 0.58
  • Revenue
  • HTD N/A
  • TBPH $80,327,000.00
  • Revenue This Year
  • HTD N/A
  • TBPH $79.82
  • Revenue Next Year
  • HTD N/A
  • TBPH N/A
  • P/E Ratio
  • HTD N/A
  • TBPH $30.93
  • Revenue Growth
  • HTD N/A
  • TBPH 27.12
  • 52 Week Low
  • HTD $16.17
  • TBPH $7.90
  • 52 Week High
  • HTD $22.13
  • TBPH $18.96
  • Technical
  • Relative Strength Index (RSI)
  • HTD 48.11
  • TBPH 74.26
  • Support Level
  • HTD $24.70
  • TBPH $14.51
  • Resistance Level
  • HTD $25.21
  • TBPH $18.96
  • Average True Range (ATR)
  • HTD 0.27
  • TBPH 0.77
  • MACD
  • HTD 0.01
  • TBPH 0.38
  • Stochastic Oscillator
  • HTD 36.67
  • TBPH 80.04

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: